Leadless Pacemakers Market Report 2026

The leadless pacemakers market size has grown rapidly in recent years. It will grow from $0.67 billion in 2025 to $0.78 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to limitations of traditional lead-based pacemakers, rising incidence of cardiac arrhythmias, growing elderly population, increasing awareness of lead-related complications, advancements in cardiac device miniaturization.

The leadless pacemakers market size is expected to see rapid growth in the next few years. It will grow to $1.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to rising demand for minimally invasive cardiac therapies, technological advancements in battery and device longevity, increasing adoption of remote patient monitoring, expansion of electrophysiology centers, growing investment in next-generation cardiac devices. Major trends in the forecast period include growing adoption of leadless cardiac pacing systems, shift toward minimally invasive cardiac implant procedures, rising preference for devices with reduced infection risk, expansion of dual-chamber leadless pacemaker development, increasing integration of remote cardiac monitoring.

The rising prevalence of heart disease is expected to drive the growth of the leadless pacemaker market in the coming years. Heart disease encompasses a variety of conditions that impact the heart’s structure or function, resulting in impaired blood flow, irregular heart rhythms, or other cardiovascular complications. The increase in heart disease is attributed to factors such as population growth and aging, lifestyle choices, stress and physical inactivity, challenges within healthcare systems, as well as genetic and environmental influences. Leadless pacemakers provide notable benefits in treating certain heart conditions by delivering effective pacing while minimizing the risk of lead-related complications and enabling a less invasive implantation procedure. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that over 35 million new cancer cases are expected by 2050, representing a 77% rise from the projected 20 million cases in 2022. Consequently, the growing incidence of heart disease is fueling the expansion of the leadless pacemaker market.

The increasing preference for minimally invasive procedures is expected to propel the growth of the leadless pacemaker market in the coming years. Minimally invasive procedures are medical interventions performed through small incisions or natural body openings using specialized instruments and imaging guidance to minimize tissue damage, pain, and recovery time while ensuring effective diagnostic or therapeutic outcomes. This rising preference is mainly driven by their ability to shorten recovery periods and reduce postoperative discomfort, prompting more patients and healthcare providers to opt for these techniques over traditional open surgeries. Leadless pacemakers facilitate minimally invasive procedures by eliminating the need for surgical pockets and transvenous leads, allowing implantation via a small catheter-based approach that minimizes tissue disruption and accelerates recovery. For example, in March 2024, a report published by the American Society of Plastic Surgeons (ASPS), a US-based professional medical organization, indicated that total cosmetic minimally invasive procedures rose from 23,672,269 in 2022 to 25,442,640 in 2023, representing a 7% year-over-year increase. Consequently, the growing preference for minimally invasive procedures is driving the leadless pacemaker market.

Major companies in the leadless pacemakers market are concentrating on creating innovative products, such as dual‑chamber systems, to enhance cardiac pacing efficiency and patient outcomes. A dual‑chamber system is a type of pacemaker that simultaneously monitors and stimulates both the atrium and the ventricle of the heart, helping maintain proper timing between the upper and lower chambers, improve blood flow, prevent irregular heart rhythms, and enhance overall cardiac function and patient quality of life. For example, in July 2023, Abbott Laboratories, a US-based medical-device company, received US Food and Drug Administration (FDA) approval for its AVEIR DR dual‑chamber leadless pacemaker system, which allows two tiny devices - one in the atrium and one in the ventricle - to communicate beat-to-beat through its implant-to-implant (i2i) technology. By removing the need for transvenous leads, this system substantially lowers the risk of infection and mechanical complications while providing more physiologic pacing. As the use of dual‑chamber leadless pacemakers increases, these advancements are expected to broaden the patient population eligible for minimally invasive cardiac pacing and improve long-term clinical outcomes.

Major companies operating in the leadless pacemakers market are Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, EBR Systems Inc., Cairdac, Imricor Medical Systems Inc., Osypka Medical GmbH, Shree Pacetronix Ltd., Lepu Medical Technology Co. Ltd., Terumo Corporation, MEDICO S.p.A., Vitatron Holding B.V., Oscor Inc., CathRx Ltd., Japan Lifeline Co. Ltd., Cardiac Pacemakers Inc., NVT AG.

North America was the largest region in the leadless pacemakers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leadless pacemakers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leadless pacemakers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the leadless pacemakers market by increasing costs of imported electronic components, micro-batteries, and precision manufacturing inputs. Advanced leadless pacing systems are most affected, particularly in north america and europe due to dependence on global medical device supply chains. Higher device costs have influenced procurement decisions in hospitals and specialty clinics. However, tariffs have encouraged localized manufacturing, regional supplier partnerships, and long-term strengthening of domestic cardiac device production capabilities.

The leadless pacemakers market research report is one of a series of new reports that provides leadless pacemakers market statistics, including leadless pacemakers industry global market size, regional shares, competitors with a leadless pacemakers market share, detailed leadless pacemakers market segments, market trends and opportunities, and any further data you may need to thrive in the leadless pacemakers industry. This leadless pacemakers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leadless pacemakers are a type of cardiac pacing device designed to deliver electrical stimulation to the heart without the use of traditional leads (wires). These self-contained devices remove the need for leads, minimizing the risk of lead-related complications such as infection, breakage, and displacement.

The main types of leadless pacemakers include micra transcatheter pacing systems and others. The micra transcatheter pacing system (TPS) is a leadless pacemaker intended to provide pacing therapy for patients with bradycardia, a condition marked by a slow or irregular heartbeat. The available pacing chambers include single-chamber and dual-chamber options. These devices are used in various settings such as hospitals, specialty clinics, and others.

The leadless pacemakers market consists of sales of single-chamber leadless pacemakers, nanostim leadless pacemakers, dual-chamber leadless pacemakers, wireless cardiac resynchronization therapy (CRT) systems, and MRI-compatible leadless pacemakers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.